Get started
Author

Werner Frings

Observed name: W. Frings
ORCID: 0000-0001-9341-4744
Observed ORCID: 0000-0001-9341-4744
OpenAlex ID: A5002775964
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
2010 · Frank R. Brennan, Laura Dill Morton, et al. · mAbs · 252
PDF
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
2017 · Takahiro Ishiguro, Yuji Sano, et al. · Science Translational Medicine · 208
Reproductive/Developmental Toxicity Assessment of Biopharmaceuticals in Nonhuman Primates
2007 · Gerhard F. Weinbauer, Werner Frings, et al. · Wiley eBooks · 33
Immunotoxicity Testing in Nonhuman Primates
2009 · Stephanie Grote-Wessels, Werner Frings, et al. · Methods in molecular biology · 20
Reproductive/Developmental Toxicity Assessment of Biopharmaceuticals in Nonhuman Primates
2010 · Gerhard F. Weinbauer, Werner Frings, et al. · Wiley eBooks · 16
Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
2022 · Shun-ichiro Komatsu, Yoko Kayukawa, et al. · Scientific Reports · 12
PDF
Effects of SA237, a humanized anti‐interleukin‐6 receptor monoclonal antibody, on pre‐ and postnatal development in cynomolgus monkey
2017 · Ryuichi Katagiri, Kana Ishihara‐Hattori, et al. · Birth Defects Research · 8
Safety Evaluation of an Fully Human Antagonist Anti-CD40 Antibody, CHIR-12.12, in a Dose Range-Finding Study in Cynomolgus Monkeys.
2004 · Ursula B. Jeffry, Kay Huh, et al. · Blood · 6
A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors.
2016 · Kenji Hashimoto, Ayesh Perera, et al. · Journal of Clinical Oncology · 5
A phase I dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.
2017 · Kenji Hashimoto, Ayesh Perera, et al. · Journal of Clinical Oncology · 4
Abstract DDT01-05: First-in-class T cell-redirecting bispecific antibody targeting glypican-3: a highly tumor-selective antigen
2016 · Takahiro Ishiguro, Yasuko Kinoshita, et al. · Cancer Research · 4
IL-21 Improves Rituximab-Mediated B Cell Depletion.
2005 · Steven D. Hughes, Rafael A. Ponce, et al. · Blood · 4
Immunological Profile and Safety Evaluation in a 23-Week Single Dose Study in Cynomolgus Monkey with CHIR-12.12, a Fully Human Antagonist Anti-CD40 Antibody.
2004 · Ursula B. Jeffry, Mohammad Luqman, et al. · Blood · 4
Study Design Considerations, Technical Procedural Aspects, Scheduling, and Dosing Sampling Volumes
2015 · Werner Frings, Marc Niehoff, et al. · Elsevier eBooks · 1
Development of anti-drug antibodies in infant and maternal non-human primates in post-natal development studies
2013 · Werner Frings, Gerhard F. Weinbauer, et al. · 1
117 Assessment of the nonhuman primate immune system by immunophenotyping: Comparison of two relevant species with the human
2003 · W. Frings, G.F. Weinbauer · Toxicology Letters · 1
Nonhuman Primates, Immunotoxicity Assessment of (Bio)Pharmaceuticals in
2015 · Werner Frings, Gerhard F. Weinbauer, et al. · Springer eBooks
Contributors
2015 · Paul Barrow, Kathryn Bayne, et al. · Elsevier eBooks
Nonhuman Primates, Immunotoxicity Assessment of (Bio)Pharmaceuticals in
2014 · Werner Frings, Gerhard F. Weinbauer, et al. · Springer eBooks
Cynomolgus monkey background data from lumbar and cisterna magna CSF collection
2012 · Werner Frings, Sven Korte, et al.
Comparison of cynomolgus and marmoset monkeys as models for biopharmaceutical drug development
2011 · Gerhard F. Weinbauer, Werner Frings
Nonhuman Primates, Immunotoxicity Assessment of Pharmaceuticals in
2006 · Werner Frings, Gerhard F Weinbauer · Springer eBooks
Assessment of the nonhuman primate immune system by immunophenotyping Comparison of two relevant species with the human
2003 · Werner Frings, G. F. Weinbauer
Works count: 23
Citation count: 579
H-index: 7
I10-index: 6
Year
Topic
Type